No added benefit of dimethyl fumarate for multiple sclerosis can be determined, as no suitable data are available, neither for a direct nor for an indirect comparison, report researchers. Dimethyl ...

The investigational drug diroximel fumarate (Vumerity, Biogen/Alkermes) showed statistically superior gastrointestinal (GI) tolerability compared with dimethyl fumarate (Tecfidera, Biogen) in patients ...

VANCOUVER — Fingolimod (Gilenya, Novartis) was better tolerated than dimethyl fumarate (Tecfidera, Biogen) in a 2-year comparison of the oral multiple sclerosis (MS) drugs. Patients receiving dimethyl ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — Women with MS who were exposed to dimethyl fumarate in the first trimester had no unexpected adverse ...

Off-label rituximab (Rituxan) led to fewer relapses over 2 years than dimethyl fumarate (Tecfidera) in people with early relapsing-remitting multiple sclerosis (MS), the phase III RIFUND-MS trial ...

Discover comprehensive details about Dimethyl Fumarate, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...

The Appraisal Committee considered evidence submitted by the manufacturer of dimethyl fumarate and a review of this submission by the Evidence Review Group (ERG). The DEFINE trial was an international ...

The appraisal committee considered evidence submitted by Almirall and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...

BOSTON--(BUSINESS WIRE)--Cycle Pharmaceuticals Limited (Cycle) is pleased to announce that Cycle Vita is now available with BAFIERTAM, expanding its patient support services in MS, following the ...

The FDA today approved Biogen and Alkermes’ diroximel fumarate, an oral agent, to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, ...

Dimethyl fumarate (trade name: Tecfidera) has been approved since January 2014 for adults with relapsing remitting multiple sclerosis (RRMS). In an early benefit assessment pursuant to the Act on the ...